I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

*M*enopause marks the end of reproductive age of the women fraternity. It is defined as the cessation of menstrual cycles for 12 consecutive months.\[[@ref1]\]

The history of menopause has several wayposts with regard to the development of treatment strategies. Testicular extract, crude ovaries, ovarian juice, and powdered ovarian tablets were used in the previous era, which followed the use of tranquilizers. The use of hormone replacement therapy (HRT) was only after medicalization of menopause. Premarin was the first marketed estrogen as a treatment of menopause in the 1940s.\[[@ref2]\]

At present, HRT is the mainstay treatment.\[[@ref3]\]

Nonhormonal treatments such as selective serotonin reuptake inhibitors, serotonin, and noradrenaline reuptake inhibitors,\[[@ref4]\] gabapentin, pregabalin, clonidine;\[[@ref5]\] phytoestrogens;\[[@ref6][@ref7]\] herbal\[[@ref8][@ref9]\] products; and various other nonpharmacological strategies are now in use.

Due to the availability of a wide range of treatment strategies, an in-depth study was required to appraise the recent prescribing trends in menopause.

The present study was carried out to assess the status of core therapy, supportive therapy, and alternative therapy in our tertiary care rural hospital of Vidarbha region -- Acharya Vinoba Bhave Rural Hospital (AVBRH), Sawangi (Meghe), Wardha, in correlation to plethora of menopausal problems.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Type of study: A monocentric hospital-based qualitative studyLocus of administrative control: Department of Pharmacology, Jawaharlal Nehru Medical College, Sawangi (Meghe), WardhaLocus of study: AVBRH, Sawangi (Meghe), WardhaStudy population: Females with menopausal symptoms coming to Obstetrics and Gynecology (OBGY) Outpatient department (OPD)/Inpatient department (IPD) of AVBRH, Sawangi (Meghe), WardhaDuration of the study: October 01, 2016--August 31, 2018Period of enrolment: October 01, 2016--December 31, 2017Period of analysis: January 01, 2018--August 31, 2018Sample size: 330.

The sample size of the study was calculated with reference to the parameter menstrual complaints,\[[@ref10]\] using the following formula:

Sample size formula for the difference between two proportions:
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Where

2α~/2~ is the critical value of normal distribution at α~/2~= 1.962 β is the critical value of the normal distribution at β = 0.84 (80% power)P~1~ is the expected sample proportion of 1^st^ group = 42.5%P~2~ is the expected sample proportion of 2^nd^ group = 44%.

Therefore,

![](JMH-10-14-g002.jpg)

n = 322.80

Ethical clearance {#sec2-1}
-----------------

The research protocol was approved in the meeting held on July 9, 2016, by the Institutional Ethics Committee and the Letter of Approval was received on July 11, 2016 (Ref. No. DMIMS (DU)/IEC/2016-17/3016).

Study design {#sec2-2}
------------

### Inclusion criteria {#sec3-1}

Women above 35 years of age who has been diagnosed with:Natural menopauseChemotherapy-induced menopausePelvic radiation-induced menopauseSurgical menopause.Menopausal women are presenting with menopausal complaintsMenopausal women who are willing to participate in the study.

### Exclusion criteria {#sec3-2}

Women below 35 years of ageWomen with a complaint of amenorrhea associated with polycystic ovarian syndromeWomen with a history of malignancy.Psychiatric disorderMusculoskeletal disorderUrogenital disorder.

Confidentiality {#sec2-3}
---------------

The identity and personal information of all the patients enrolled in the study was kept strictly confidential.

Statistical analysis {#sec2-4}
--------------------

With the help of the statistician working in the Department of Community Medicine, JNMC, Sawangi (Meghe), Wardha, the collected data were statistically analyzed using descriptive and inferential statistics using Chi-square test to ascertain the clinical significance of the present study. The software used in the analysis was SPSS 22.0 version and GraphPad Prism 6.0 version (Armonk, NY: IBM Corp.) and *P* \< 0.05 is considered as the level of statistical significance.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Incidence of different types of menopause {#sec2-5}
-----------------------------------------

The incidence of natural menopause was found to be maximum which was followed by surgical menopause. In comparison to the year 2016, the incidence of natural menopause was decreased, whereas surgical menopause was increased in the year 2017 \[[Table 1](#T1){ref-type="table"}\].

###### 

Incidence of natural menopause, chemotherapy-induced menopause, pelvic radiation-induced menopause, and surgical menopause

  Year   Natural menopause, *n* (%)   Chemotherapy-induced menopause, *n* (%)   Pelvic radiation-induced menopause, *n* (%)   Surgical menopause, *n* (%)
  ------ ---------------------------- ----------------------------------------- --------------------------------------------- -----------------------------
  2016   151 (90.96)                  0                                         0                                             15 (09.03)
  2017   140 (85.36)                  0                                         0                                             24 (14.63)

2.48, *P*=0.11, NS, *P*\>0.05. NS: Not significant

Treatment modalities {#sec2-6}
--------------------

Pharmacotherapy and surgery were the main treatment modalities used to treat menopausal complaints of the patients visiting OBGY OPD of AVBRH, Sawangi (Meghe), Wardha \[[Graph 1](#G1){ref-type="fig"}\].

![Treatment modalities for menopausal complaints](JMH-10-14-g003){#G1}

Routes of drug administration {#sec2-7}
-----------------------------

Drug administration in maximum number of patients was Oral, followed by Vaginal, Topical and Injectables \[[Graph 2](#G2){ref-type="fig"}\].

![Routes of drug administration](JMH-10-14-g004){#G2}

Types of pharmacotherapy {#sec2-8}
------------------------

Pharmacotherapy was further divided into core therapy, supportive therapy, and alternative therapy according to the type of drug. Drugs for treating the primary menopausal complaint were included in the core therapy; vitamins, supplements, and those drugs used to prevent the side effects of core drugs were included in the supportive therapy; whereas drugs other than allopathic were included under alternative therapy \[[Graph 3](#G3){ref-type="fig"}\].

![Different types of pharmacotherapy](JMH-10-14-g005){#G3}

Core drugs (*n* -- 239, % - 84.75) {#sec2-9}
----------------------------------

The drugs used in core therapy were further classified according to the Anatomical Therapeutic Chemical (ATC) classification system \[[Table 2](#T2){ref-type="table"}\].

###### 

Taxonomic profile of the core drugs used in menopausal women

  Drugs              NPN                                                                    Dosage form   ROA       Dose                                            FOA        DOT        ATC code   Number of patients   Percentage of patients
  ------------------ ---------------------------------------------------------------------- ------------- --------- ----------------------------------------------- ---------- ---------- ---------- -------------------- ------------------------
  Candid cream       Clotrimazole                                                           Ointment      Topical   1%                                              BD         7 days     D01AC01    5                    02.09
  Candid B cream     Clotrimazole + Beclometasone                                           Ointment      Topical   0.025% + 1%                                     BD         7 days     D07CC04    20                   08.37
  Candid V pessary   Clotrimazole                                                           Tablet        Vaginal   200 mg                                          HS         7 days     G01AF02    9                    03.77
  Clid V pessary     Clindamycin + Metronidazole + Clotrimazole + Lactobacillus sporogens   Tablet        Vaginal   100 mg + 100 mg + 100 mg + 150 million spores   HS         7 days     G01A       34                   14.23
  Estrogen cream     Estradiol                                                              Ointment      Topical   0.1 mg/1g                                       BD         7 days     G03CA03    2                    0.84
  OC pills           Levonorgestrel + Ethinyl estradiol                                     Tablet        Oral      0.15 mg + 0.03 mg                               OD         3 months   G03FA11    4                    01.67
  Primolut - N       Norethisterone                                                         Tablet        Oral      5 mg                                            BD         5 days     G03DC02    1                    0.42
  Flucos             Fluconazole                                                            Tablet        Oral      150 mg                                          HS         1 days     J02AC01    2                    0.84
  Norflox            Norfloxacin                                                            Tablet        Oral      400 mg, 100 mg                                  1/w        4 weeks    J01MA06    15                   06.28
  Doxy               Doxycycline                                                            Tablet        Oral      100 mg                                          BD         7 days     J01AA02    94                   39.33
  Metro              Metronidazole                                                          Tablet        Oral      400 mg                                          TDS        7 days     J01XD01    85                   35.56
  C Tax - O          Cefixime                                                               Tablet        Oral      200 mg                                          BD         7 days     J01DD08    9                    03.77
  FAS 3 kit          Fluconazole + Azithromycin + Secnidazole                               Tablet        Oral      150 mg + 1000 mg + 1000mg                       OD         1 days     J01RA07    1                    0.42
  Nitrofur           Nitrofurantoin                                                         Tablet        Oral      100 mg                                          TDS        7 days     J01XE01    3                    01.26
  Norflox TZ         Norfloxacin + Tinidazole                                               Tablet        Oral      400 mg + 600 mg                                 BD         7 days     J01RA13    4                    01.67
  CitalCitralka      Disodium hydrogen citrate                                              Syrup         Oral      1.37g/5 ml, 1.53g/5 ml                          10 ml BD   7 days     G04BX      42                   17.57
  BuscopanHyocimax   Hyoscine Butylbromide                                                  Tablet        Oral      100 mg, 10 mg                                   BD         3 days     A03BB01    32                   13.39
  Brufen             Ibuprofen                                                              Tablet        Oral      400 mg                                          BD         3 days     M01AE01    4                    01.67
  Tramadol           Tramadol                                                               Tablet        Oral      400 mg, 100 mg                                  BD         3 days     N02AX02    5                    02.09
  Meftal spas        Dicyclomine + Mefenamic acid                                           Tablet        Oral      10 mg + 250 mg                                  BD SOS     3 days     A03D       6                    02.51
  PCM                Paracetamol                                                            Tablet        Oral      500 mg                                          BD         3 days     N02BE01    1                    0.42
  Pause              Tranexamic acid                                                        Tablet        Oral      500 mg                                          BD TDS     5 d3 d     B02AA02    24                   10.04
  Ceriz              Cetirizine                                                             Tablet        Oral      10 mg                                           HS         3 days     R06AE07    2                    0.84
  Betadine pessary   Povidone iodine                                                        Tablet        Vaginal   200 mg                                          HS         5 days     G01AX11    1                    0.42

NPN: Nonproprietary name, DOT: Duration of therapy, FOA: Frequency of administration, ROA: Route of administration, ATC: Anatomical therapeutic chemical, BD: Twice a day, HS: Bedtime, TDS: Three times a day, OD: Once a day

Imidazole and triazole derivatives of topical antifungals: Candid cream (Clotrimazole) was used topically in 2.09% of menopausal women on core therapyCombination of topical corticosteroid with antibiotics: Candid B cream (Clotrimazole + Beclometasone) was used topically in 8.37% of menopausal women on core therapyImidazole derivative of gynecological anti-infectives and antiseptics: Tablet Candid V pessary (Clotrimazole) was used intravaginally in 3.77% of menopausal women on core therapyGynecological anti-infective drugs: Tablet Clid V pessary (Clindamycin + Metronidazole + Clotrimazole + Lactobacillus sporogens) was used intravaginally in 14.23% of menopausal women on core therapyPlain preparation of natural and semisynthetic estrogens: Estrogen cream (Estradiol) was used topically in 0.84% of menopausal women on core therapyProgesterone and estrogen fixed combinations: OC pills (Levonorgestrel + Ethinylestradiol) were taken orally by 1.67% of menopausal women on core therapyProgesterone derivatives: Tablet Primolut -- N (Norethisterone) was taken orally by 0.42% of menopausal women on core therapyTriazole derivative of systemic antimycotics: Tablet Flucos (Fluconazole) was used orally in 0.84% of menopausal women on core therapyFluoroquinolone group of antibacterial drugs: Tablet Norflox (Norfloxacin) was used orally in 6.28% of menopausal women on core therapyTetracycline group of antibacterial drugs: Tablet Doxy (Doxycycline) was used orally in 39.33% of menopausal women on core therapyOther antibacterial drugs: Tablet Metro (Metronidazole) was used orally in 35.56% of menopausal women on core therapyThird-generation cephalosporins: Tablet C Tax--O (Cefixime) was used orally in 3.77% of menopausal women on core therapyCombinations of antibacterials: FAS 3 kit tablets (Fluconazole + Azithromycin + Secnidazole) were used orally in 0.42% of menopausal women on core therapyNitrofuran derivative of antibacterial drugs: Tablet Nitrofur (Nitrofurantoin) was used orally in 1.26% of menopausal women on core therapyTablet Norflox TZ (Norfloxacin + Tinidazole) was used orally in 1.67% of menopausal womenUrologic drugs: Syrup Cital and Syrup Citralka (Disodium hydrogen citrate) were used orally in 17.57% of menopausal women on core therapyBelladonna alkaloids, semisynthetic, quaternary ammonium compounds: Tablet Buscopan and Tablet Hyocimax (Hyoscine butylbromide) were used orally in 13.39% of menopausal women on core therapyPropionic acid derivatives of nonsteroidal anti-inflammatory and antirheumatic products: Tablet Brufen (Ibuprofen) was used orally in 1.67% of menopausal women on core therapyOpioid group of analgesic drugs: Tablet Tramadol was used orally in 2.09% of menopausal women on core therapyCombination of antispasmodic with analgesic drugs: Tablet Meftal spas (Dicyclomine + Mefenamic acid) were used orally in 2.51% of menopausal women on core therapyAnalgesic and antipyretic drugs: Tablet PCM (Paracetamol) was used orally in 0.42% of menopausal women on core therapyAntifibrinolytic drugs: Tablet Pause (Tranexamic acid) was used orally in 10.04% of menopausal women on core therapyPiperazine derivative of antihistaminics for systemic use: Tablet Ceriz (Cetirizine) was used orally in 0.84% of menopausal women on core therapyGynecological antiseptics: Tablet Betadine pessary (Povidone iodine) was used intravaginally in 0.42% of menopausal women on core therapy.

Supportive therapy (*n* -- 134, % - 47.52) {#sec2-10}
------------------------------------------

The drugs used in supportive therapy were further classified according to the ATC classification system \[[Table 3](#T3){ref-type="table"}\].

###### 

Taxonomic profile of supportive drugs used in menopausal women

  Drugs          NPN                                                                                                                            Dosage form        ROA         Dose           FOA        DOT                   ATC code   Number of patients   Percentage of patients
  -------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------ ----------- -------------- ---------- --------------------- ---------- -------------------- ------------------------
  Multivitamin   Vitamin A, B1, B2, B3, B5, B6, B7, B12, C, D3, E, Calcium, Iron, Cu, Mn, Zn, Magnesium oxide, P, Sodium molybdate, and Boron   Tablet Injection   Oral I.V.   10 ml          ODBDStat   30 days15 days1 day   A11AA      8                    05.97
  B-colen NS     Pine bark extract, carbohydrates, sugar, vitamin C, B3, B5, B1, B2, B12 and B6, lysine, zinc sulfur, and copper sulfate        Syrup              Oral        10 ml          BD         1 month               A11AB      22                   16.42
  Rantac         Ranitidine                                                                                                                     Tablet             Oral        150 mg         ODBD       3 days7 days          A02BA02    85                   63.43
  Iron           Iron                                                                                                                           Tablet             Oral        200 mg100 mg   OD         1 month               B03A       14                   10.45
  Calcium        Calcium                                                                                                                        Tablet             Oral        1 g 500 mg     OD         1 month               A12AA      25                   18.66
  Vitamin D      Cholecalciferol                                                                                                                Granules           Oral        50000 IU       1/week     1 month               A11CC55    6                    04.48

NPN: Nonproprietary name, DOT: Duration of therapy, FOA: Frequency of administration, ROA: Route of administration, ATC: Anatomical therapeutic chemical, BD: Twice a day, HS: Bedtime, TDS: Three times a day, OD: Once a day

### Multivitamin combinations {#sec3-3}

Multivitamin with minerals

Multivitamin tablets and injections (Vitamin A, B1, B2, B3, B5, B6, B7, B12, C, D3, E, Calcium, Iron, Cu, Mn, Zn, Magnesium oxide, P, Sodium molybdate, and Boron) were used in 5.97% of the menopausal women who were on supportive therapy to improve their general health.

Multivitamin with other combinations

B-colen NS syrup (Pine bark extract, carbohydrates, sugar, Vitamin C, B3, B5, B1, B2, B12, and B6, lysine, zinc sulfur, and copper sulfate) was used orally in 16.42% of patients on supportive therapy.

### Drugs for peptic ulcer and gastroesophageal reflux disease {#sec3-4}

Rantac (Ranitidine) was prescribed to 63.43% of menopausal women on supportive therapy.

### Iron preparations {#sec3-5}

Iron tablets were used in 10.45% of menopausal women on supportive therapy.

### Mineral supplements {#sec3-6}

Calcium tablets were used in 18.66% of menopausal women on supportive therapy.

### Vitamin D preparation {#sec3-7}

Vitamin D granules (Cholecalciferol) were used in 04.48% of menopausal women on supportive therapy.

Alternative therapy (*n* -- 9, % - 3.19) {#sec2-11}
----------------------------------------

Herbal preparation: Evening primrose oil in the form of tablets and capsules were used orally in 66.67% of patients on alternative medicineAyurvedic preparation: Syrup M2 Tone is an Ayurvedic medicine which contains Ashoka, Ashwagandha, Cedrus Deodara, Kasisa Bhasma, Lodhra, Mesua Ferrea, Nardostachys Jatamansi, and Shatavari as active ingredients. It was used Orally in 33.33% of patients on alternative medicine \[[Graph 4](#G4){ref-type="fig"}\].

![Alternative drug preparations used in menopausal women](JMH-10-14-g006){#G4}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The incidence of natural menopause decreased in the year 2017 as compared to 2016, which can be explained by the finding of increased incidence of surgical menopause.

During the literature search, no studies with similar results were found as the number of studies evaluating the incidence of various types of menopause has not been conducted yet. However, a research conducted by the Study of Women\'s Health Across the Nation roughly estimated that 5% of women belonging to the age group of 40--45 years, whereas 25% of women in 45--55 years\' experience natural menopause.\[[@ref11]\]

Unni\[[@ref12]\] and Syamala and Sivakami\[[@ref13]\] also showed similar finding that the incidence and prevalence of premature menopause including surgical menopause is increasing at an alarming rate in India, especially in the states such as Andhra Pradesh, Gujarat, and Karnataka.

During the study, there was no incidence of chemotherapy or pelvic radiation-induced menopause. However, the study by Shuster *et al*.\[[@ref14]\] is suggestive of an increased incidence of chemotherapy and pelvic radiation-induced menopause, which they associated it to the increased and better treatment strategies of cancer in all the age groups of women, and exposure to higher doses of alkylating agents and higher doses of radiation to the ovaries during cancer therapy makes women more likely to experience ovarian failure.

Pharmacotherapy and surgery were the main treatment modalities used for menopausal complaints of the patients visiting OBGY OPD of AVBRH, Sawangi (Meghe), Wardha.

During the study, the use of hormonal therapy was very less; Estradiol cream 0.84%, Levonorgestrel + Ethinyl estradiol oral contraceptive pills 01.67%, and Norethisterone 0.42%. Estradiol cream was used as monotherapy and in combination for urogenital symptoms such as increased frequency of micturition, burning micturition, and itching in the vulva region. Levonorgestrel + Ethinyl estradiol oral contraceptive pills were used for abnormal uterine bleeding and dysfunctional uterine bleeding as a monotherapy; whereas norethisterone was used for dysfunctional uterine bleeding as a monotherapy.

These findings are in contrast to the findings by Hackley and Rousseau,\[[@ref15]\] Santoro *et al*.,\[[@ref16]\] and Panay *et al*.,\[[@ref17]\] which showed the maximum use of HRT to manage various urogenital symptoms such as hot flashes and musculoskeletal symptoms. However, Rousseau\[[@ref18]\] in her study revealed that the primary care physicians showed a lower rate of hormonal therapy recommendations.

Similarly, Hersh *et al*.\[[@ref19]\] in their study revealed that the use of HRT has considerably declined.

During the study, the maximum drugs used in core therapy had a symptomatic cure approach with an effort to minimize the use of HRT. Maximum drugs used were antibiotics of various groups.

Multivitamin, Iron, Calcium, and Vitamin D were used for pain in the abdomen, white discharge, backache, dysfunctional uterine bleeding, abnormal uterine bleeding, uterine prolapse, vaginal erosions, and menorrhagia as a supportive therapy. Ranitidine was prescribed as a supportive drug along with antibiotics and pain killers, so as to reduce the gastrointestinal side effects of these drugs.

A herbal preparation of evening primrose oil (66.67%) in the form of tablets and capsules; and an Ayurvedic preparation Syrup M2 Tone (33.33%) was used as alternative medicines for the treatment of menopausal symptoms.

Evening primrose oil was used in combination with calcium and Vitamin D supplements for hot flush, mastalgia, white discharge, and pain abdomen.

Syrup M2 Tone was used as a monotherapy for abnormal uterine bleeding in two patients and in combination with tablet Pause (Tranexamic acid) in one patient.

Ohn Mar *et al*.\[[@ref20]\] in their study on the use of alternative medications showed a similar finding that evening primrose oil is the most used alternative medication (18.1%) which is followed by use of soy-based products (12.3%), green tea (6.8%), and gingko (5.8%).

Mehrpooya *et al*.\[[@ref21]\] in their study concluded that herbs such as black cohosh and evening primrose oil are effective in reducing the severity of hot flashes, but black cohosh is more effective than evening primrose oil.

Limitation of the study {#sec2-12}
-----------------------

As the present study was carried out in a rural setup, there was lack of awareness in females about the various clinical manifestations of menopause, and therefore, there was underreporting of few categories of symptoms in our studyDue to time constraint, no follow-ups were conducted in the present study. Therefore, assessment of the status outcome after the treatment was out of scopeAs the data of the present study were collected only from the OBGY Department of AVB Rural Hospital, Sawangi (Meghe) Wardha, patients bypassing the OBGY department to other department according to the type of menopausal complaint could not be addressed.
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